NCT01779401View on ClinicalTrials.gov

Clopidogrel Response Evaluation and AnTi-Platelet InterVEntion in High Thrombotic Risk PCI Patients

NACompletedINTERVENTIONAL

Enrollment

1,078

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

September 30, 2016

Study Completion Date

September 30, 2016

Conditions

Coronary Heart Disease

Interventions

DRUG

Clopidogrel 75mg

DRUG

Clopidogrel 150mg

DRUG

Aspirin 100mg

DRUG

Cilostazol 100mg

Trial Locations (2)

100037

Fuwai Cardiovascular Hospital, Beijing

Unknown

Fuwai Cardiovascular Hospital, Beijing

Sponsors

Collaborators (1)

Haemonetics Corporation

All Listed Sponsors

collaborator

Beijing Municipal Health Bureau

OTHER

collaborator

Haemonetics Corporation

INDUSTRY

collaborator

Zhejiang Otsuka Pharmaceutical Co., Ltd.

INDUSTRY

lead

Chinese Academy of Medical Sciences, Fuwai Hospital

OTHER